Diabetologia 46 , 798801 (2003)
Liraglutide treatment markedly decreased food consumption and body weight in the control group under both chow-fed and high-sucrose-fed conditions
served on scientific advisory panels and/or speakers bureaus and served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi
This complexity offers both challenges and opportunities for therapeutic targeting, as selective modulation of pathogenic NETosis may be achievable without compromising essential antimicrobial defense
Clinical studies show average weight loss of 15-20% of total body weight results that were previously achievable only through bariatric surgery
Kothny, W., Lukashevich, V., Foley, J